PT  - JOURNAL ARTICLE
AU  - Majdoubi, Abdelilah
AU  - Michalski, Christina
AU  - O’Connell, Sarah E.
AU  - Dada, Sarah
AU  - Narpala, Sandeep
AU  - Gelinas, Jean
AU  - Mehta, Disha
AU  - Cheung, Claire
AU  - Basappa, Manjula
AU  - Liu, Aaron C.
AU  - Görges, Matthias
AU  - Barakauskas, Vilte E.
AU  - Mehalko, Jennifer
AU  - Esposito, Dominic
AU  - Sekirov, Inna
AU  - Jassem, Agatha N.
AU  - Goldfarb, David M.
AU  - Douek, Daniel C.
AU  - McDermott, Adrian B.
AU  - Lavoie, Pascal M.
TI  - Antibody reactivity to SARS-CoV-2 is common in unexposed adults and infants under 6 months
AID  - 10.1101/2020.10.05.20206664
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.05.20206664
4099  - http://medrxiv.org/content/early/2020/11/06/2020.10.05.20206664.short
4100  - http://medrxiv.org/content/early/2020/11/06/2020.10.05.20206664.full
AB  - Background Pre-existing antibody reactivity against SARS-CoV-2 in unexposed people is a potentially important consideration for COVID-19 severity and vaccine responses. However, it has been difficult to quantify due to a lack of reliable defined background titers in unexposed individuals.Methods We measured IgG against multiple SARS-CoV-2 antigens, SARS-CoV and other circulating coronavirus spike proteins using a highly sensitive multiplex assay, and total SARS-CoV-2 spike-specific antibodies (IgG/M/A) using a commercial CLIA assay in 276 adults from the Vancouver area, Canada between May 17th and June 19th 2020. Reactivity threshold in unexposed individuals were defined comparing to pre-pandemic sera and to sera from infants under 6 months of age.Results The seroprevalence from a SARS-CoV-2 exposure, adjusted for false-positive and false-negative test results, was 0.60% in our adult cohort. High antibody reactivity to circulating endemic coronaviruses was observed in all adults and was ∼10-fold lower in infants <6 months. Consistent with a waning of maternal antibodies, reactivity in infants decreased more than 50-fold ∼8 months later. SARS-CoV-2 Spike, RBD, NTD or nucleocapsid antibody reactivity >100-fold above that of older infants was detected in the vast majority of unexposed adults and pre-pandemic sera. This antibody reactivity correlated with titers against circulating coronaviruses, but not with age, sex, or whether adults were healthcare workers.Conclusion A majority of unexposed adults have pre-existing antibody reactivity against SARS-CoV-2. The lack of similar antibody reactivity in infants where maternal antibodies have waned suggests that this cross-reactivity is acquired, likely from repeated exposures to circulating coronaviruses.Funding BC Children’s Hospital Foundation, NIH/NIAIDCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis study is not a clinical trialFunding StatementThis study was funded by the BC Children's Hospital Foundation (to PML) and the Intramural Research Program of the Vaccine Research Centre (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH; to ABM and DCD). The funders did not play a role in the design, planning, execution, analysis or publication of the study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study procedures were approved by the University of British Columbia (UBC) Children's & Women's Research Ethic Board (H20-01205; H18-01724).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNon-identifying metadata will be made public (in process); participant-specific demographic data may be made available later, or to external investigators upon request, if can be agreed by participants and after obtaining permissions from relevant institutional ethics review boards...